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Abstract Gly-332 is a conformationally important residue of
the Tn10-encoded metal-tetracycline/H antiporter (TetA(B)),
which was found by random mutagenesis and confirmed by site-
directed mutagenesis. A bulky side chain at position 332 is
deleterious to the transport function. A spontaneous second-site
suppressor revertant was isolated from G332S mutant and
identified as the Ala-354CAsp mutant. Gly-332 and Ala-354 are
located on opposite ends of transmembrane segment XI. As
judged from [14C]NEM binding to Cys mutants, the residue at
position 354, which is originally exposed to water, was buried in
the membrane by a G332S mutation through a remote
conformational change of transmembrane segment XI. This
effect is the same as that of a G62L mutation at position 30
through transmembrane segment II [Kimura, T., Sawai, T. and
Yamaguchi, A. (1997) Biochemistry 36, 6941^6946]. Interest-
ingly, the G332S mutation was also suppressed by the L30S
mutation, and the G62L mutation was moderately suppressed by
the A354D mutation. These results indicate the presence of a
close conformational relationship between the flanking regions of
the transmembrane segments II and XI.
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1. Introduction
The transposon Tn10-encoded tetracycline resistance pro-
tein (TetA(B)) is a metal-tetracycline/H antiporter [2]. It ac-
tively e¥uxes tetracyclines using the H concentration gra-
dient across the membrane as an energy source [3,4]. It is a
polytopic inner membrane protein whose 12 membrane-span-
ning structure was experimentally established by Kimura et al.
[5] by means of site-speci¢c chemical labeling of Cys-intro-
duced mutants.
Functionally important residues of TetA(B) have been in-
vestigated by site-directed mutagenesis [6^11], and their dis-
tribution is mainly localized around transmembrane segments
I, II and III, and segments VII, VIII and IX, and their £ank-
ing loop regions. In this study, new important residues were
searched for in the whole TetA(B) protein by random muta-
genesis. Random mutagenesis was performed with hydroxyl-
amine [12]. When double-stranded DNA molecules are treated
with hydroxylamine, a 4-amino group of cytosine is hydroxy-
lated. The resulting hydroxylaminocytosine is matched to ad-
enine when DNA is replicated. Therefore, a C-G base pair is
randomly changed to a T-A base pair. On random mutagen-
esis, we found a mutation of Gly-332, which is located in
cytoplasmic loop 10^11 in the putative topology (Fig. 1).
The position of Gly-332 in the putative topology of TetA(B)
resembles that of Gly-62, that is, both are located at the
cytoplasmic end of a transmembrane segment, the second seg-
ment from the C-terminal and N-terminal ends, respectively.
In our previous study, we showed that a bulky side chain at
position 62 inhibits activity [13]. In addition, mutation of the
residue at position 62 to one having a bulky side chain is
suppressed by a second-site suppressor mutation of Leu-30,
which is opposite to Gly-62 across the membrane [1]. In this
study, we found that the mutation of Gly-332 was also sup-
pressed by a mutation at the opposite side of the membrane.
In addition, the mutations of Gly-62 and Gly-332 were mu-
tually suppressed by the other’s suppressor mutations, indicat-
ing a close conformational relationship between the regions
£anking the second transmembrane helices from the N- and
C-terminal ends.
2. Materials and methods
2.1. Materials
N-[Ethyl-1-14C]maleimide (1.5 GBq/mmol) was purchased from Du-
Pont-New England Nuclear, USA. The oligonucleotides used for site-
directed mutagenesis were synthesized by Sawady Technologies (To-
kyo, Japan). All other materials were of reagent grade and obtained
from commercial sources.
2.2. Bacterial strains and plasmids
Escherichia coli CJ236 [14] were used for oligonucleotide-directed
mutagenesis by the Kunkel method [14]. E. coli TG1 [15] and W3104
[16] were used for transformation after mutagenesis and expression of
the tet gene, respectively. pCT1183 [17] and pLGT2 [10] are high copy
number and low copy number plasmids, respectively, carrying 2.45 kb
Tn10-tetA(B) and tetR gene fragments. pCT1183 and pLGT2 were
used for mutagenesis and expression of the tetA(B) gene, respectively.
2.3. Random mutagenesis
A low copy number plasmid, pLGT2 (Km and TC), which encodes
the tetR and tetA(B) genes, was treated with 0.4 M hydroxylamine in
50 mM sodium phosphate bu¡er (pH 6.0) at 70‡C for 1 h. After
transformation of E. coli TG1 cells with the resulting plasmids, colo-
nies resistant to 50 Wg/ml kanamycin and sensitive to 50 Wg/ml tetra-
cycline were picked up by replica plating. TetA(B) expression was
judged on Western blotting of the sonicated membranes using anti-
TetA(B)-C-terminal-peptide antiserum. In order to limit the mutation
site, EcoRV^EcoRI (485 bp) and EcoRI^BamHI (868 bp) fragments
of these mutant plasmid DNAs, which encode the N-terminal half
(Ile-39^Ser-199) and C-terminal half (Asn-200^Ala-401) of TetA(B),
respectively, were isolated and recombined with the corresponding
fragments of pLGT2. After the measurement of the drug resistance
of these recombinant plasmids in E. coli TG1, the mutation sites were
assigned by DNA sequencing.
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2.4. Site-directed mutagenesis
Site-directed mutagenesis was performed by the Kunkel method [14]
using pCT1183 as a template, and the synthetic oligonucleotides con-
taining mismatches generating a codon change and silent mismatches
generating new restriction sites in order to check the mutations. Mu-
tations were ¢rst detected as the appearance of new restriction sites
and then veri¢ed by DNA sequencing using an ALFexpress DNA
sequencer (Pharmacia Biotech). Then the mutant tetA(B) gene was
transferred into pLGT2 through corresponding fragment exchange.
2.5. Determination of tetracycline resistance
The tetracycline resistance of E. coli cells harboring pLGT2 or a
mutant plasmid of it was determined by the agar dilution method and
expressed as the minimum inhibitory concentration (MIC).
2.6. Assaying of the reaction of [14C]N-ethylmaleimide (NEM) with
TetA(B) proteins




By means of random mutagenesis as described above, we
picked up 1084 colonies resistant to 50 Wg/ml kanamycin,
from which 47 clones were sensitive to tetracycline
(MIC6 50 Wg/ml). Among them, 34 clones showed TetA(B)
expression (pLGT M1^M34), as judged on Western blotting
of the sonicated membranes using anti-Ct14 antiserum (data
not shown). Mutation sites which caused a decrease in drug
resistance were found to be localized in the C-terminal half
(10 clones), N-terminal half (1 clone), upstream region of the
tetA(B) gene (5 clones), or multiple regions including the C-
terminal half (18 clones). Among the 11 mutants of which the
mutation sites were only localized in the C- or N-terminal
half, six showed tetracycline MICs of higher than 12.5 Wg/
ml. The other ¢ve mutants showed MIC values of less than
1.6 Wg/ml and were analyzed in the following experiments.
Three of them were found to contain a mutation at codon
332 from GGT (Gly) to AGT (Ser), and two of them con-
tained a double mutation at codons 332 (same as above) and
377 from TGT (Cys) to TAT (Tyr). The MIC values of the
G332S single mutant and G332S/C377Y double mutant were
1.6 and 0.8 Wg/ml, respectively. In our previous study [18] we
showed that Cys-377 is not important for the tetracycline
transport function. Thus, the decrease in the drug resistance
of these random mutagenesis mutants is mainly due to the
mutagenesis at position 332.
3.2. Site-directed mutagenesis at codon 332
In order to con¢rm the importance of Gly-332 in the Te-
tA(B) function, Gly-332 was replaced with Ser, Ala, Cys, Asp
or Leu by site-directed mutagenesis. The mutant proteins were
normally expressed in E. coli cells, as detected on Western
blotting using anti-TetA(B)-C-terminal-peptide antiserum
(data not shown). The tetracycline resistance levels of E. coli
cells expressing these mutant genes are shown in Table 1.
G332D and G332L mutants showed no tetracycline resist-
ance. On the other hand, G332S (MIC 1.6 Wg/ml) and
G332C (6.3 Wg/ml) mutants showed very low resistance, and
mutant G332A showed moderate resistance (12.5 Wg/ml). The
MIC values seem to re£ect the side chain volume of the res-
idue at position 332. These results are very similar to the
results of mutations of Gly-62, which is located at the boun-
dary between cytoplasmic loop2-3 and transmembrane seg-
ment II in the N-terminal half of TetA(B). On the other
hand, Gly-332 is located at the boundary between cytoplasmic
loop 10^11 and transmembrane segment XI in the putative
topology of TetA(B) (Fig. 1).
Fig. 1. Putative secondary structure of the TetA(B) protein. The structure was con¢rmed by site-directed chemical labeling of the Cys mutants
of TetA(B) [5]. Large bold letters indicate the important glycine residues described in this manuscript and the residues replaced by the second-
site suppressor mutation. Roman numerals indicate the transmembrane helices. Transmembrane helices II and XI are enclosed by bold frames.
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3.3. Isolation of second-site suppressor mutants from the
G332S mutant
In our previous paper [1], we reported that the mutation of
Gly-62 is suppressed by a mutation of Leu-30, which is lo-
cated at the opposite side of the membrane. Thus, we tried to
isolate a second-site suppressor mutant from the G332S mu-
tant. 1.0 ml of an E. coli cell suspension (OD610 = 1.4) harbor-
ing pLGG332S was applied to an agar plate containing 50 Wg/
ml tetracycline, followed by incubation at 37‡C for 5 days. As
a result, 15 colonies were isolated and the plasmids (pLGT
R1^R15) were prepared from these revertant cells. The DNA
sequences of 14 revertants showed a simple back mutation at
codon 332 from AGT (Ser) to GGT (Gly). Only one (pLGT
R1) showed a second-site mutation at codon 354 from GCT
(Ala) to GAT (Asp). Codon 332 of pLGT R1 was not
changed from that of pLG G332S. pLGT R1 had an addi-
tional mutation in the palindromic sequence of the promoter
OL region, in which two thymidines at positions 47 and 48
bases upstream from the ¢rst codon of TetA(B) were deleted
(vTT).
E. coli cells harboring pLGT R1 showed an MIC value of
50 Wg/ml; however, the expression of the mutant protein was
drastically reduced (data not shown). It was reported by
Weissmann et al. [19] that deletion of thymidine in the OL
region of the tet operon caused a decrease in the tetA(B)
gene expression. The vTT/G332S mutant without the
A354D mutation showed no recovery of tetracycline resist-
ance (Table 1). In contrast, the G332S/A354D double mutant,
which was constructed by site-directed mutagenesis, showed
normal expression and a MIC value of 25 Wg/ml (Table 1),
while the expression of this mutant signi¢cantly slowed down
the cell growth.
Ala-354 is located on the periplasmic surface of the mem-
brane (Fig. 1), thus the suppression must be due to the remote
conformational e¡ect of A354D mutation similar to the case
of the suppression by the L30S mutation of the G62L mutant.
Ala-354 itself is not mandatory for the TetA(B) function be-
cause all of the single Ala-354 mutants almost completely
retained the wild-type tetracycline resistance level (100 Wg/
ml) (Table 1). When Ala-354 was replaced with a residue
other than Asp in G332S mutants, the resulting double mu-
tant showed moderate or weak recovery of the drug resistance
(Table 1).
3.4. Remote conformational change caused by G332S mutation
In the case of G62L mutation, the side chains at positions
29 and 30, which in the wild-type protein are exposed to the
periplasmic side, are embedded in the membrane through a
remote conformational change, and the suppressor mutation
of L30S blocks this conformational change [1]. Therefore, the
e¡ect of the G332S mutation on the degree of exposure of the
side chain at position 354 was examined. The high reactivity
Table 1
Tetracycline resistance levels of E. coli W3104 cells harboring a wild-type or mutant tetA(B) gene
Mutant Minimum inhibitory concentration (MIC) of tetracycline (Wg/ml)
No plasmid 0.8
pLGT2 (wild) 200
pLGT M2 (G332S/C377Y)a 0.8



















G332S L30S A354C 12.5
G332S L30C 6.3





G62L L30C A354D 50
G62L A354C 1.6
G62L L30S A354D 100
a
These plasmids were obtained by random mutagenesis. The others except for pLGT R1 plasmid were constructed by site-directed mutagenesis.
b
This plasmid was obtained from spontaneous mutations of pLGG332S. vTT indicates the deletion of two thymidines at position 47 and 48
bases upstream from the ¢rst codon of the tetA(B) gene.
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of [14C]NEM with the A354C single mutant indicates that the
side chain at position 354 is originally exposed to the aqueous
phase (Fig. 2). In contrast, the G332S/A354C double mutant
hardly reacted with NEM (Fig. 2), certainly indicating that
the side chain at position 354 is also buried in the membrane
through the remote conformational e¡ect of the G332S muta-
tion, similar to the case of the G62L/L30C double mutant [1].
3.5. Mutual cross conformational suppressions of mutations of
Gly-62 and Gly-332
Since the mechanism of A354D suppression of mutant
G332S seems very similar to that of mutant G62L suppressed
by L30S mutation, we tested the cross suppression of mutants
G332S and G62L by L30S and A354D mutations, respec-
tively. Surprisingly, the G332S/L30S double mutant showed
a MIC value of 25 Wg/ml, which is the same level as the
G332S/A354D revertant mutant (Table 1). In the case of the
G62L mutant, the A354D mutation caused very low but sig-
ni¢cant suppression (Table 1). Especially, it should be noted
that A354D mutation caused signi¢cant a synergistic e¡ect of
suppression on the G62L mutant in combination with the
L30C mutation (Table 1).
As judged by [14C]NEM binding, position 354 in the A354C
mutant was buried into the membrane by the G62L mutation
as well as by the G332S mutation (Fig. 2) and position 30 in
the L30C mutant was also buried into the membrane by the
G332S mutation (Fig. 2) as well as by the G62L mutation [1].
In addition, position 354 in the G332S/A354C double mutant
and position 30 in the G332S/L30C double mutant were re-
exposed by L30S and A354D suppressor mutations, respec-
tively (Fig. 2). From the MIC values, it is clear that the peri-
plasmic positions 30 and 354 were embedded in the membrane
in the inactive form of TetA(B) and exposed to water phase in
the active one. These results indicate the presence of close
conformational interactions between the regions £anking the
transmembrane segments II and XI.
4. Discussion
In the previous study, we observed that absence of bulky
side chains on Gly-62 is important for the function of TetA(B)
because any mutation of Gly-62 caused the complete loss of
the tetracycline export activity [13], except for the Ala mutant.
In this study, we found a new glycine residue at position 332
which is important for the TetA(B) function. Similar to Gly-
62, the mutations of Gly-332 caused a drastic decrease or
complete loss of the tetracycline resistance except for the
Ala mutant. The glycine residues of which mutations to glu-
tamic acid residues decreases the tetracycline resistance were
also found in loop 10^11 of the pBR322-encoded TetA(C)
[20]. Our result indicates that the bulky side chain is delete-
rious at these glycine positions. Similar role of glycine residues
are widely observed in major facilitator superfamily transport-
ers, for example, Jung et al. [21] reported the similar delete-
rious e¡ect of the bulky side chains at some glycine positions
(Gly-64, Gly-115 and Gly-147) in lactose permease. Gly-332 is
also conserved in lactose permease, of which a cysteine mu-
tant showed a signi¢cant decrease in the lactose transport
activity [22].
As reported in our previous paper [1], the mutation of Gly-
62 caused a signi¢cant conformational change around posi-
tion 30 which is located on the opposite side of the membrane
resulting in the embedding of this area into the membrane.
The second-site suppressor mutation at position 30 recovered
Fig. 2. The binding of [14C]NEM to the mutant TetA(B) proteins. In these experiments, equal amounts of the sonicated membranes (1 mg
membrane protein per each sample) were used for incubation with [14C]NEM. After solubilization, the TetA(B) proteins were precipitated with
anti-TetA(B) C-terminal antiserum and PANSORBIN [1], followed by SDS-polyacrylamide gel electrophoresis. The expression levels of the mu-
tant TetA(B) proteins were slightly di¡erent from each other, therefore, the NEM binding level was normalized by the amount of TetA(B) pro-
teins in panel B. A: Upper panel: Coomassie brilliant blue staining of the SDS-polyacrylamide gel containing the immuno-precipitated TetA(B)
proteins. This is a typical result out of three independent experiments. Lane 1: A354C; lane 2: G332S/A354C; lane 3: G62L/A354C; lane 4:
L30C; lane 5: L30C/G332S; lane 6: L30S/G332S/A354C; lane 7: L30C/G332S/A354D. Lower panel: Radioactive bands visualized with a
BAS-1000 Bio Imaging Analyzer. The lanes are the same as in the upper panel. B: The amount of bound [14C]NEM normalized with respect
to the amount of the TetA(B) protein. The data are shown as the average of the results of three independent experiments. The amounts of
[14C]NEM and the TetA(B) protein were calculated from the densities of the radioactive bands and Coomassie brilliant blue-stained bands
measured with a BAS-1000 Bio-Imaging Analyzer Fuji Film (Tokyo, Japan) and a GS-700 Imaging Densitometer (Bio-Rad), respectively. The
values are expressed as percentages of the average level of the L30C mutant values.
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the transport function through the blocking of such a remote-
conformational change. Similar remote suppression of glycine
mutants was also reported in pBR322-encoded TetA(C) [23]
and in lactose permease [24]. Jessen-Marshall et al. [24] re-
ported that the mutation of Gly-64 in lactose permease, which
corresponds to Gly-62 in TetA(B), is suppressed by a variety
of second-site mutations distributed in the mid-transmem-
brane region and on the periplasmic surface of the membrane.
They argued that the loop 2^3 region containing Gly-64 in
lactose permease is a conformationally sensitive region which
facilitates the conformational change on the opposite side of
the membrane [25,26]. Other mutations in TetA(B) in this
region were also suppressed by a second-site mutation on
the opposite side of the membrane [27]. Therefore, the re-
mote-conformational suppression against mutations in a con-
formationally sensitive site may be a general rule for major
facilitator superfamily transporters [28]. In this study, we
found that another remote-conformationally sensitive site is
present in the C-terminal half. It is interesting that the muta-
tions at Gly-62 and Gly-332 caused the similar conformation-
al change in the regions around position 30 and 354 located
on the periplasmic side of the membrane and both glycine
mutants were suppressed by the second-site mutations oc-
curred in either region. These results indicate the presence
of a close conformational linkage in these regions and
strongly suggested the close proximity of loop 1^2 and loop
11^12 as reported in lactose permease [29^31].
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